Literature DB >> 16100033

Assessment of hemostatic risk factors in predicting arterial thrombotic events.

David Feinbloom1, Kenneth A Bauer.   

Abstract

Arterial thrombosis results from endovascular injury and, to a lesser extent, alterations in hemostatic equilibrium. Although multiple hereditary and acquired hemostatic risk factors have been described in the pathophysiology of venous thrombosis, the degree and type of abnormalities that contribute to arterial thrombosis are less well understood. Endothelial cell injury with the elaboration of proinflammatory mediators stimulates the process of arterial thrombosis. Although this is most often the result of endovascular injury attributable to atherosclerotic disease, other disease states can elicit a similar response as well. Similarly, once thrombosis has been initiated, variations in the activity of coagulation proteins and endogenous anticoagulants, as well as the kinetics of platelet aggregation, may alter the effectiveness of thrombus formation. Epidemiological studies have identified several acquired or inherited states that may result in endothelial damage or altered hemostatic equilibrium, thereby predisposing patients to arterial thrombosis. These include hyperhomocysteinemia, elevated C-reactive protein, antiphospholipid antibodies, elevated fibrinogen, Factor VII, plasminogen activator inhibitor-1 (PAI-1), hereditary thrombophilias, and platelet hyper-reactivity. This review explores our present understanding of these risk factors in the development of arterial thrombotic events. At present, the literature supports a role for hyperhomocysteinemia, elevated C-reactive protein, and elevated fibrinogen as risk factors for arterial thrombosis. Similarly, the literature suggests that lupus anticoagulants and, to a lesser extent, elevated titers of cardiolipin IgG antibodies predispose to arterial vascular events. In certain subsets of patients, including those with concomitant cardiac risk factors, <55 years of age, and women, hereditary thrombophilias such as carriership of the factor V Leiden and the prothrombin G20210A mutations may confer a higher risk of arterial thrombosis. However, the data on Factor VII, PAI-1, and platelet receptor polymorphisms are contradictory or lacking.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100033     DOI: 10.1161/01.ATV.0000181762.31694.da

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

1.  Replication and characterisation of genetic variants in the fibrinogen gene cluster with plasma fibrinogen levels and haematological traits in the Third National Health and Nutrition Examination Survey.

Authors:  Janina M Jeff; Kristin Brown-Gentry; Dana C Crawford
Journal:  Thromb Haemost       Date:  2012-01-25       Impact factor: 5.249

2.  Change in cardiovascular risk factors with progression of kidney disease.

Authors:  Linda F Fried; Ronit Katz; Mary Cushman; Mark Sarnak; Michael G Shlipak; Lewis Kuller; Anne B Newman
Journal:  Am J Nephrol       Date:  2008-10-24       Impact factor: 3.754

3.  Coagulation parameters and platelet function analysis in patients with acromegaly.

Authors:  A Colak; H Yılmaz; Y Temel; M Demirpence; N Simsek; İ Karademirci; U Bozkurt; E Yasar
Journal:  J Endocrinol Invest       Date:  2015-06-06       Impact factor: 4.256

Review 4.  Arterial thrombus formation in cardiovascular disease.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher
Journal:  Nat Rev Cardiol       Date:  2011-07-05       Impact factor: 32.419

5.  Inducible nitric oxide synthase provides protection against injury-induced thrombosis in female mice.

Authors:  Rita K Upmacis; Hao Shen; Lea Esther S Benguigui; Brian D Lamon; Ruba S Deeb; Katherine A Hajjar; David P Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-20       Impact factor: 4.733

6.  Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis.

Authors:  Shelley E Crary; Sarah Troendle; Naveed Ahmad; George R Buchanan
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

7.  Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.

Authors:  G H Tofler; J Massaro; C J O'Donnell; P W F Wilson; R S Vasan; P A Sutherland; J B Meigs; D Levy; R B D'Agostino
Journal:  Thromb Res       Date:  2016-02-03       Impact factor: 3.944

8.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

9.  Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.

Authors:  R Kaiser; C M Cleveland; L A Criswell
Journal:  Ann Rheum Dis       Date:  2008-09-09       Impact factor: 19.103

10.  Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  R Kaiser; J L Barton; M Chang; J J Catanese; Y Li; A B Begovich; L A Criswell
Journal:  Genes Immun       Date:  2009-05-07       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.